

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Scan this QR Code to view this Addendum.



## AVIENCE BIOMEDICALS LIMITED (Formerly known as Avience Biomedicals Private Limited)

**Corporate Identification Number: U29299PN2009PLC133737**

Our Company was incorporated as Avience Biomedicals Private Limited under the provisions of the Companies Act, 2013 vide certificate of incorporation dated December 23, 2019, in Delhi. Subsequently, our Company was converted into a Public Limited Company pursuant to Shareholders Resolution passed at the Extra Ordinary General Meeting of the Company held on June 26, 2024 and the name of our Company was changed from "Avience Biomedicals Private Limited" to "Avience Biomedicals Limited" vide a fresh Certificate of Incorporation dated September 03, 2024 having CIN U74999DL2019PLC359158 issued by the Registrar of Companies, Central Processing Centre, Delhi. The registered office of our company is situated at C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India. For further details, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 221 of this Draft Red Herring Prospectus.

**Registered Office:** C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India  
**Website:** [www.avienbio.com](http://www.avienbio.com); **E-Mail:** [info@avienbio.com](mailto:info@avienbio.com) **Telephone No:** 1800-12-04-636  
**Company Secretary and Compliance Officer:** Mr. Manoj Kumar

**PROMOTER OF OUR COMPANY: MR. DHARAM DEO CHOUDHARY, MR. RAM NAGINA CHOUDHARY, MR. JANARDAN PAL AND MS. DEEPA CHOUDHARY**

### ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED SEPTEMBER 15, 2025 NOTICE TO INVESTORS (THE "ADDENDUM")

**INITIAL PUBLIC OFFER OF UP TO 16,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("THE EQUITY SHARES") OF AVIENCE BIOMEDICALS LIMITED ("OUR COMPANY" OR "ABL" OR THE "ISSUER") AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [●] LAKHS ("PUBLIC ISSUE") OUT OF WHICH 80,400 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹[●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 15,27,600 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [●] AND [●] % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.**

Potential Bidders may note the following:

1. Under the heading titled "Definitions and Abbreviations" beginning from page 02 of the Draft Red Herring Prospectus, has been updated to insert the Abbreviations under Industry and Technical terms as Suggested by NSE.
2. Under the heading titled "Risk Factor" beginning from page 28 of the Draft Red Herring Prospectus, certain risk factors has been inserted, updated and there is change in Sequence of risk factor numbers as suggested by NSE.
3. Under the heading titled "General Information" beginning from page 66 of the Draft Red Herring Prospectus, monitoring agency has been updated as suggested by NSE.
4. Under the heading titled "Capital information" beginning from page 77 of the Draft Red Herring Prospectus, The table presents the current shareholding pattern of our Company as on the date of this Draft Red Herring Prospectus has been updated as suggested by NSE.
5. Under the heading titled "Objects of the Issue" beginning from page 91 of the Draft Red Herring Prospectus the Expected and Existing capacity and Rationale has been updated as suggested by the NSE.
6. Under the heading titled "Our Business" beginning from page 148 of the Draft Red Herring Prospectus and accordingly, certain information has been updated as suggested by NSE.
7. Under the heading titled "Management's Discussion and Analysis of Financial Condition and Result of Operations" beginning from page 265 of the Draft Red Herring Prospectus Rationale for increase in PAT Margin has been inserted as suggested by NSE.
8. Under the heading titled "Outstanding Litigations and material developments" beginning from page 280 of the Draft Red Herring Prospectus Status of Litigation has been updated.
9. Under the heading titled "Government and Other Statutory Approvals" beginning from page 299 of the Draft Red Herring Prospectus the Shop & Establishment has been updated as suggested by NSE.
10. Please note that all other details in, and updates to the Red Herring Prospectus/ Prospectus with respect to issue price and/or other relevant details will be carried out in the Red Herring Prospectus, as and when filed with ROC, SEBI and the Stock Exchange.

The above is to be read in conjunction with the Draft Red Herring Prospectus and accordingly their references in the Draft Red Herring Prospectus stand amended pursuant to this Addendum. Please note that the changes pursuant to this Addendum will be appropriately included in the Red Herring Prospectus/ Prospectus, as and when filed with the RoC, the SEBI and the Stock Exchanges. All capitalized terms used in this Addendum shall, unless the context otherwise requires, have the meaning ascribed to them in the Draft Red Herring Prospectus.

**On behalf of Avience Biomedicals Limited**  
**Sd/-**  
**Manoj Kumar**  
**Company Secretary & Compliance Officer**

Place: Delhi  
Date: September 15, 2025

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
	
<b>FINTELLECTUAL CORPORATE ADVISORS PRIVATE LIMITED</b> <b>Corporate office:</b> B-20, Second Floor, Sector-1, Noida-201301, Uttar Pradesh, India <b>Tel. No.:</b> +91 1204266080 <b>Email:</b> <a href="mailto:ipo@fintellectualadvisors.com">ipo@fintellectualadvisors.com</a> <b>Investor Grievance Email:</b> <a href="mailto:investors@fintellectualadvisors.com">investors@fintellectualadvisors.com</a> <b>Website:</b> <a href="http://www.fintellectualadvisors.com">www.fintellectualadvisors.com</a> <b>Contact Person:</b> Mr. Amit Puri/ Mr. Pramod Negi <b>SEBI Registration Number:</b> INM000012944 <b>CIN:</b> U74999DL2021PTC377748	<b>SKYLINE FINANCIAL SERVICES PRIVATE LIMITED</b> <b>Address:</b> D-153A, First Floor, Okhla Industrial Area, Phase-I, New Delhi 110020 <b>Tel. No.:</b> 011-40450193-197 <b>Email:</b> <a href="mailto:ipo@skylinerta.com">ipo@skylinerta.com</a> <b>Investor Grievance E-mail:</b> <a href="mailto:grievances@skylinerta.com">grievances@skylinerta.com</a> <b>Website:</b> <a href="http://www.skylinerta.com">www.skylinerta.com</a> <b>Contact Person:</b> Mr. Anuj Rana <b>SEBI Registration Number:</b> INR000003241 <b>CIN:</b> U74899DL1995PTC071324
BID/OFFER PERIOD	
<b>BID/OFFER OPENS ON: [●]</b>	<b>BID/OFFER CLOSES ON: [●]</b>

Our Company in consultation with the Book Running Lead Managers may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/ Offer Opening Date.

***This space has been left blank intentionally***

## TABLE OF CONTENTS

<b>TITLE</b>	<b>PAGE NO.</b>
<b>SECTION I – GENERAL</b>	<b>2</b>
DEFINITIONS AND ABBREVIATION	2
<b>SECTION III – RISK FACTORS</b>	<b>3</b>
<b>SECTION V: GENERAL INFORMATION</b>	<b>11</b>
<b>SECTION VI: CAPITAL STRUCTURE</b>	<b>12</b>
<b>SECTION VII – PARTICULARS OF THE ISSUE</b>	<b>13</b>
OBJECTS OF THE ISSUE	13
<b>SECTION VIII – ABOUT THE COMPANY</b>	<b>16</b>
OUR BUSINESS	16
<b>SECTION IX - FINANCIAL STATEMENTS</b>	<b>20</b>
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF OPERATIONS	20
<b>SECTION X- LEGAL AND OTHER INFORMATION</b>	<b>22</b>
OUTSTANDING LITIGATIONS AND MATERIAL DEVELOPMENTS	22
GOVERNMENT AND OTHER STATUTORY APPROVALS	42
<b>SECTION XIV – OTHER INFORMATION</b>	<b>43</b>
DECLARATION	43

*This space has been left blank intentionally*

## SECTION I – GENERAL SECTION

### DEFINITIONS AND ABBREVIATIONS

The terms ‘EHS’ and ‘CPPP’ are defined under the "Technical and Industry-Related Terms" section on page 12 of Draft Red Herring Prospectus.

Term	Description
EHS	Environment, Health and Safety
CPPP	Central Public Procurement Portal

*This space has been left blank intentionally*

## SECTION III – RISK FACTORS

### **Existing Risk factor no. 3 has been Revised as follows:**

**RF-3. *We rely on suppliers for medical devices and equipment manufacturers for our trading goods, and also face risks in sourcing raw materials and components from third parties for the manufacturing and assembly of our medical equipment. Any disruption in the supply of these goods or materials could adversely impact our business, operations, and financial condition.***

We rely on suppliers for a range of traded goods, including medical equipment, surgical instruments, consumables, laboratory reagents, and diagnostic equipment, with whom we typically do not have long-term contracts or exclusive supply agreements. Orders are placed on a requirement basis. While we have experienced disruption in the supply of raw materials or components during the COVID period and also faced some occasional delays in sourcing such goods, except these there have been no major disruptions that have materially affected our business operations or financial condition. Any failure by our suppliers to meet agreed timelines, whether due to regulatory issues, financial difficulties, or other factors, may lead to delays, increased costs, payment issues, or damage to our reputation, all of which could adversely impact our business, operations, and financial condition.

Any disruption in the supply of raw materials or components, including issues such as facility damage, power outages, labour unrest, or geopolitical events, could cause delays, increased costs, and operational disruptions, further affecting our business and cash flows. If such disruptions occur, we would need to source alternative suppliers, which could lead to additional delays and increased costs, negatively impacting our financial condition. However, we have not experienced any significant disruptions in the sourcing of traded goods or raw materials and components for our manufacturing processes.

### **The Risk Factor 12 has been shifted to Risk Factor 5.**

**RF-5 *Our business derives a significant portion of its revenue from the trading sector, and any potential instability in this area could pose a risk to our overall performance.***

We derive a significant portion of our revenue from trading activities. As depicted in below mentioned table:

*(Amount in ₹ lakhs)*

Particulars	For the March 31, 2025	%*	For the March 31, 2024	%*	For the March 31, 2023	%*
	<b>Standalone</b>					
Trading	2,089.06	72.31%	1,293.84	79.60%	915.29	83.81%
Manufacturing	789.27	27.32%	331.67	20.40%	176.77	16.19%
Sale of Services	10.63	0.37%	-	-	-	-
<b>Total</b>	<b>2,888.95</b>	<b>100.00%</b>	<b>1625.51</b>	<b>100.00%</b>	<b>1,092.06</b>	<b>100.00%</b>

*% of Revenue from operation*

Given this distribution, it can be understood that significant portion of our sales belonged to the aforesaid activity. Any adverse effects experienced within this activity could also have a detrimental impact on our business.

While our current revenue distribution indicates significant reliance on trading business, we are actively pursuing strategies to diversify our business portfolio. This effort aims to reduce dependence on Trading business and ensure a more balanced and resilient revenue base

### **Existing Risk Factor No. 5 has been Revised and Shifted to Risk Factor 6 as follows:**

**RF-6 *The purchase and sale of medical devices and equipment for our trading activities are significantly dependent on related parties.***

The purchase and sale of traded goods, including medical equipment, consumables, and laboratory reagents, are significantly influenced by transactions with our wholly owned subsidiary, DR Meditech Surgical and Diagnostics Private Limited, and sales to related parties.

The purchase and sale for three financial year is as follows:-

*(in ₹ lakhs, except %)*

Particulars	March 31, 2025	March 31, 2024	March 31, 2023
*Purchases from DR Meditech Surgical and Diagnostics Private Limited	154.75	136.50	156.39
% of Total Purchase	8.86%	9.12%	15.87%
*Sales to DR Meditech Surgical and Diagnostics Private Limited	642.58	667.17	669.48
% of Revenue from operations	22.24%	41.04%	61.30%

*\*Note: The purchases and sales are inclusive of GST.*

The company undertakes the transaction entered into by the Company are on an arm's length basis and as per applicable provisions of the Companies Act and other applicable laws. While we believe that this transaction have been conducted on an arm's length basis, it is difficult to determine whether more favourable terms could have been achieved with unrelated parties. Additionally, we anticipate that we may engage in related party transactions in the future. For more details, please refer to the section titled "Related Party Transactions" on page 253 of this Draft Red Herring Prospectus.

**Existing Risk Factor No. 9 has been Revised as follows:**

***Our business depends on the efficient functioning of our manufacturing facilities and assembly units. Although we have not received any product-related complaints, occasional machinery breakdowns in the past highlight the importance of regular maintenance and operational enhancements. Any unforeseen obsolescence, damage, theft, or delays in repair could have an adverse impact on our operations, cash flows, financial condition, and results.***

Our business is dependent on the efficient functioning of our manufacturing and assembly facilities, including our manufacturing unit located at G-1, Sector-11, Noida, Distt.- Gautam Budh Nagar, Uttar Pradesh. While our Company has not received any complaints regarding product quality, we have encountered machinery breakdowns in the past. To mitigate such risks, we have strengthened our preventive maintenance programs, invested in advanced equipment, and implemented robust monitoring systems to enhance operational efficiency.

Our facilities are subject to various operating risks, including breakdowns and failures of equipment, industrial accidents, severe weather conditions, natural disasters, and other events beyond our control. Any significant malfunction may entail substantial repair and maintenance costs, cause operational delays, and, in some cases, require temporary suspension of operations until repairs are completed or replacement machinery is procured. Planned shutdowns for cleaning, statutory inspections, maintenance, capacity expansion, or equipment upgrades may also impact production schedules.

Obsolescence, destruction, theft, or breakdowns of machinery could significantly increase capital expenditure requirements, accelerate depreciation, and affect the estimated useful life of assets. In some cases, replacement or repair of major machinery or parts may be costly and subject to supply shortages, inflationary pressures, transportation constraints, or unavailability. Such events may not be fully covered by insurance, which could adversely affect our business operations, cash flows, financial condition, and results. Nonetheless, our continuous focus on infrastructure improvement, proactive maintenance, and operational resilience is aimed at ensuring seamless production, timely deliveries, and sustained customer satisfaction.

#### **New Risk factor is included as RF-10**

***RF-10- We import a portion of our raw material supply from China. Restrictions on or import duties relating to materials and equipment imported for our manufacturing operations as well as restrictions on or import duties levied on our products in our export markets may adversely affect our business prospects, financial performance and cash flows.***

A portion of our raw materials is sourced from China, which constituted 5.18%, 31.33% and 22.47% of our total raw material procurement in FY 2022-23, FY 2023-24 and FY 2024-25, respectively. Any restrictions on imports, changes in trade policies, imposition of higher import duties, delays in customs clearance, adverse geo-political developments, or supply chain disruptions may affect the availability and cost of such raw materials. Further, any increase in import duties on raw materials required for our manufacturing operations or export duties levied on our finished products could increase our input costs and reduce the competitiveness of our products. These factors may materially and adversely impact our business prospects, financial performance, cash flows and operations. For further details, please refer to the chapter titled “Our Business” beginning on page 148 of this Draft Red Herring Prospectus.

#### **The Risk factor 13 has been revised as follows:**

***RF-13 Our Company has reported negative cash flows in the recent period. Negative cash flows in the future could adversely affect our results of our operations and financial condition.***

Our cash flows from operating activities, investing activities and financing activities based on consolidated Financial Statement as Restated basis for financial year ended March 31, 2025, and 2024 are set forth below:

<i>( Amount in ₹ lakhs)</i>		
Particulars	Financial Year ended 31-Mar-25	Financial Year ended 31-Mar-24
Cash flow from operating activities	333.38	98.50
Cash flow from investing activities	(952.63)	(402.77)
Cash flow from financing activities	1,024.66	296.72
Net Increase / (Decrease) in cash and cash equivalents	405.41	(7.56)

Our cash flows from operating activities, investing activities and financing activities based on standalone Financial Statement as Restated basis for financial year ended March 31 2025, 2024 and 2023 are set forth below:

<i>(Amount in ₹ lakhs)</i>			
Particulars	Financial Year ended 31-Mar-25	Financial Year ended 31-Mar-24	Financial Year ended 31-Mar-23
Cash flow from operating activities	313.89	23.13	158.73
Cash flow from investing activities	(816.08)	(412.20)	(193.62)
Cash flow from financing activities	905.80	380.06	43.28
Net Increase / (Decrease) in cash and cash equivalents	403.62	(9.01)	8.39

Negative cash flows in certain periods were primarily due to capital expenditure made during the respective financial years exceeding the cash generated from operating activities and financing activities. These investments in plant and equipment, Land were undertaken to enhance capacity, improve operational efficiency, and support long-term growth, and were funded through a combination of internal accruals and financing activities.

#### **The Risk factor 28 has been shifted to Risk Factor 15.**

***RF-15 We have in the past entered into related party transactions and we may continue to do so in the future.***

We have in the past entered into below mentioned related party transactions with our Promoter, Directors and Key Managerial Personnels, Subsidiaries etc. For further details, please refer to the chapter titled - “Financial Statements as

Restated” at page 263. While we assert that all our related party transactions have been conducted at arm's length, and we confirm compliance with relevant provisions of the Companies Act and other applicable laws, we cannot guarantee that we might not have secured more favourable terms if these transactions had involved unrelated parties.

(Amount in ₹ lakh)

Name of Related Party	Nature of Relationship	Nature of Transaction	Amount of transaction during the year ended March 31, 2025	%*	Amount of transaction during the year ended March 31, 2024	%*	Amount of transaction during the year ended March 31, 2023	%*
Dharam Deo Choudhary	KMP (Managing Director)	Remuneration	30.00	1.02%	7.50	0.45%	8.00	0.73%
		Share Issued (Right)	33.18	1.12%	-	0.00%	15.41	1.41%
		Share Issued (Bonus)	-	0.00%	-	0.00%		0.00%
		Purchase of Investment in equity /Repay by Issue of Share	-	0.00%	414.77	24.93%		0.00%
		Loan Taken	129.09	4.37%	227.26	13.66%	0.40	0.04%
		Loan Repaid	92.12	3.12%	-	0.00%	7.59	0.69%
Ram Nagina Choudhary	KMP (Whole Time Director)	Share Issued (Right)	12.66	0.43%	-	0.00%	16.39	1.50%
		Share Issued (Bonus)	-	0.00%	-	0.00%	17.56	1.61%
		Loan Taken	19.00	0.64%	32.81	1.97%	-	0.00%
		Loan repaid	32.81	1.11%		0.00%		0.00%
		Purchase of Investment in Equity/Repay by Issue of Share	-	0.00%	158.21	9.51%	-	0.00%
		Director Remuneration's	7.29	0.25%	-	0.00%	0	0.00%
Janardan Pal	KMP - Non Executive Director	Remuneration	2.35	0.08%	6.00	0.36%	11.00	1.01%
		Director sitting fees	0.41	0.01%		0.00%		0.00%



		Share Issued (Right)	-	0.00%	-	0.00%	6.41	0.59%
		Share Issued (Bonus)	-	0.00%	-	0.00%	9.62	0.88%
		Loan Taken	-	0.00%	18.39	1.11%	-	0.00%
Manoj Kumar Aggarwal	KMP	Director sitting fees	0.09	0.00%	-	0.00%	-	0.00%
Pankaj Sharma	KMP	Director sitting fees	0.41	0.01%	-	0.00%	-	0.00%
Aditya Pal	Relative's of KMP	Remuneration	1.12	0.04%		0.00%		0.00%
Om Prakash pal	Additional Independent Director	Director sitting fees	0.27	0.01%		0.00%		0.00%
Manoj Kumar	KMP (Company Secretary)	Remuneration	2.18	0.07%		0.00%		0.00%
Saurabh Verma	KMP (Chief Financial Officer)	Remuneration	7.09	0.24%	-	0.00%	-	0.00%
Deepa Choudhary	KMP (from 23 Aug 2024)/Relative Key Managerial Person	Legal & Professional Fees	7.06	0.24%	18.00	1.08%	12.00	1.10%
		Share Issued (right)	-	0.00%	-	0.00%	10.62	0.97%
		Share Issued (Bonus)	-	0.00%	-	0.00%	10.01	0.92%
		Remuneration	14.58	0.49%	-	0.00%	-	0.00%
DR Meditech Surgical and Diagnostics Private Limited	Enterprise in which Key managerial personnel or their relatives have significant influence	Sales (Including GST)	642.58	21.75%	667.17	40.10%	669.48	61.23%
		Purchase (Including GST)	154.75	5.24%	136.50	8.21%	156.39	14.30%
		Purchase of Assets (Including GST)	-	0.00%		0.00%		0.00%
		Amount Paid	20.69	0.70%	80.75	4.85%	33.50	3.06%
		Amount Received	716.58	24.26%	551.65	33.16%	837.37	76.59%
		Expenses Paid by DR Meditech (Net of Reimbursement)	(132.32)	-4.48%	(7.87)	-0.47%	13.77	1.26%

**% of Total Income.**

It is likely that our Company may enter into related party transactions in the future. Such related party transactions may potentially involve conflicts of interest. We cannot assure you that such transaction, individually or in the aggregate, will always be in the best interests of our Company and/or that it will not have an adverse effect on our business and results of operations.

### **Risk Factor 17 has been updated**

***RF-17 Delay in registration of Products in multiple geographical locations across the world may affect our revenue generation and overall financial performance.***

One of the key issue is to secure the registration of our various products in multiple geographical locations across the world. The product registration process varies significantly from country to country, as it is governed by the respective regulatory authorities in each jurisdiction. These processes can be complex, lengthy, and time-consuming, with no standardized or guaranteed timeframe for approval provided by the respective health authorities however company has not faced any major delay in registration of products.

Given the variability and unpredictability of the regulatory processes in different regions, there is a risk that we may not be able to obtain the necessary approvals for our future products in a timely manner. This delay in product registration could impact our ability to launch products as planned, thereby potentially affecting our revenue generation and overall financial performance

### **New Risk factor has been included as RF-18**

***RF-18 Any change in Government policies or reduction in tender-based opportunities may affect our business operations and financial performance.***

A small portion of our business is derived from contracts awarded by the Central and/or State Governments and their agencies, which are typically allocated through a tender-based procurement process. Any reduction in budgetary allocations, delays in project execution, withdrawal of schemes, changes in policies or priorities, or shift in outsourcing strategies by such authorities may reduce the availability of such projects and impact our business opportunities.

The tender process is competitive and subject to eligibility, technical, and financial criteria, which may change over time. Further, factors such as macroeconomic conditions, political developments, or other unforeseen circumstances may affect the demand for our products or services. While we are not significantly dependent on Government contracts, any adverse change in the availability or terms of such opportunities could have an adverse effect on our business operations and financial results.

### **New Risk factor has been included as RF-20**

***RF- 20 Under-utilization of our manufacturing facilities could adversely affect our business operations and financial performance.***

The information relating to our installed capacities utilization disclosed in this Draft Red Herring Prospectus is based on various assumptions and estimates of our management, These estimates have also been subject to rounding off. Actual production levels and utilization rates may differ materially from the estimated figures or historical trends disclosed. Accordingly, undue reliance should not be placed on the installed capacity or capacity utilization information included herein.

If we are unable to achieve optimal capacity utilization of our manufacturing facilities, whether due to an reduced demand, operational inefficiencies, or other factors, our business operations, growth prospects, cash flows, and financial performance could be adversely affected. Extended periods of under-utilization, or significant short-term under-utilization, may also result in reduced operational efficiency and profitability. For details of our installed capacity and utilization in the last three financial years, please refer to “Our Business – Capacity Installed and Capacity Utilization of the Company” on page 151 of this Draft Red Herring Prospectus.

### **Risk Factor 26 has been updated as follows:**

***RF-26 Our success depends on stable and reliable logistics and transportation infrastructure. Disruption of logistics and transportation services could impair the ability of our suppliers to deliver raw materials or our ability to deliver products to our customers and/ or increase our transportation costs, which may adversely affect our operations.***

We rely on third-party transportation services for the movement of raw materials and products to and from our suppliers and customers, using both road and freight ships. While this mode of transportation carries inherent risks—such as accidents (collisions, groundings), natural hazards (storms, fires, explosions, lightning), and external factors (political instability, berth availability for cargo ships, and event-related restrictions) that could potentially cause delays or

disruptions—we have not experienced any significant interruptions in the past. Nonetheless, in the event such risks materialize, they may impact our ability to procure raw materials or meet delivery schedules efficiently, and we may need to maintain higher raw material inventory levels, which could increase our costs.

**New Risk factor has been included as RF-28, RF-31, RF-31, RF-32 and RF-35**

***RF- 28 Product liability claims and product recalls could harm our reputation, business, financial condition, cash flows and results of operations.***

Our business is exposed to product liability claims and potential product recalls, which could have a significant impact on our reputation, financial condition, and operations. Any defect, safety concern, or adverse reaction arising from the use of our products could lead to claims from customers, healthcare professionals, or regulatory bodies, resulting in legal disputes, compensation costs, and reputational damage.

If a product is found to be non-compliant with regulatory standards or poses safety risks, we may be required to initiate a recall, leading to financial losses, regulatory penalties, and disruption in supply chains. Additionally, repeated recalls or product-related issues could undermine consumer confidence, reduce demand for our products, and impact long-term brand credibility.

As on the date of this Draft Red Herring Prospectus, we do not have product liability insurance coverage, which further exposes us to financial risk in the event of product-related claims or recalls. Any significant liability claim could result in high legal expenses, settlements, or compensation costs, which would have to be borne directly by the company, impacting our cash flows and financial stability.

Managing product liability risks requires strict quality control, regulatory compliance, and risk mitigation strategies. However, without insurance coverage, we remain vulnerable to potential financial and legal consequences arising from unexpected product-related issues, which could adversely affect our business operations and market position. Risk related to stringent domestic and foreign applicable regulation and any adverse regulatory action may materially adversely affect our financial condition and business operations.

***RF-31 We are subject to stringent domestic and foreign regulations, and any failure to obtain, renew, or maintain requisite approvals, or any adverse regulatory action, may materially and adversely affect our business, results of operations, and financial condition.***

Our business operations are subject to extensive regulation under various domestic and, where applicable, foreign laws relating to safety, health, environment, labor, and other governmental requirements. We are required to obtain, maintain, and periodically renew statutory and regulatory approvals, accreditations, licenses, and registrations from various governmental and regulatory authorities. Any failure or delay in applying for, obtaining, or renewing such approvals, or any suspension, revocation, or expiry of existing approvals, may impede our operations and adversely impact our financial performance.

***RF 32 Our revenue is dependent on the maintenance of existing product lines and service relationships, as well as the market acceptance of new products, services, and innovations.***

A significant portion of our revenue is derived from our existing product lines and long-standing service relationships with customers. Any deterioration in the quality, relevance, or competitiveness of these offerings, or the loss of key customer relationships, could adversely affect our business performance. In addition, our ability to grow and sustain revenue depends on the successful development, introduction, and market acceptance of new products, services, and technological innovations. Failure to anticipate market trends, adapt to evolving customer preferences, or achieve desired performance and reliability standards for new offerings could result in lower-than-expected sales, reduced margins, or loss of market share. These factors, individually or collectively, could have a material adverse effect on our business, results of operations, and financial condition.

***RF- 35 The issuer company does not have any comparable Indian listed peers & the peers which have been disclosed in the red herring prospectus may have a different business model as compared to our company.***

The issuer company does not have any comparable Indian listed peers, making it challenging to benchmark its performance, valuation, and business model against publicly traded companies in India. While certain private companies who are peers of our Company have been disclosed in the red herring prospectus, their business models may differ

significantly from ours, leading to limitations in direct comparisons for investors and stakeholders. The absence of directly comparable listed companies may affect market perception, investor confidence, and pricing expectations, as potential investors may rely on international benchmarks or companies with different operational structures. Differences in business models, revenue streams, or geographic focus may lead to challenges in accurately assessing industry position, growth potential, and financial metrics. As a result, investors may find it difficult to evaluate our company's competitive positioning, which could impact market valuation, demand for shares, and overall investor interest.

**Risk Factor 39 has been revised as follows:**

***RF-39 We rely on professional staff to be appointed by the company for the Research and Development Activities.***

One of our future plans is to establish a Research and Development (R&D) Center within our company. Currently, we have four employees engaged in R&D activities; however, we have not yet identified or secured a fully qualified and legitimate team to comprehensively lead and conduct the R&D efforts necessary for the development of our future products. These products are intended to be manufactured and marketed under our brand. The absence of a fully formed and experienced R&D team may pose a significant risk to our ability to innovate and successfully bring new products to market, potentially affecting our competitive position and overall business growth.

**Risk Factor 42 has been revised as follows:**

***RF-42 We also sell our products through network of distributors and dealers and any inability to expand or effectively manage our growing distribution and sales network may have an adverse effect on our business, results of operations and financial condition.***

In addition to direct sales of our products to end-user customers, we also operate through an extensive sales and distribution network. We are dependent on our channel partners, including dealers and distributors, for the distribution of our products. As of FY 2022-23, we were engaged with 50 dealers, which increased to 52 in FY 2023-24 and 61 in FY 2024-25. Our ability to expand and grow our product reach significantly depends on the reach and effective management of our distribution network. We continuously seek to increase the penetration of our products by appointing new distributors and dealers targeted at different markets and geographies. However, we cannot assure you that we will be able to successfully identify and appoint new distributors or effectively manage our existing network. If the terms offered to such distributors or dealers by our competitors are more favourable than those offered by us, they may decline to distribute our products and terminate their arrangements with us.

*This space has been left blank intentionally*

## SECTION V: GENERAL INFORMATION

### **Paragraph related to Monitoring Agency has been updated on page 71 of the Draft Red Herring Prospectus:**

Since our Issue size does not exceed ₹ 5,000.00 Lakhs, we are not required to appoint monitoring agency for monitoring the utilization of Net Proceeds in accordance with Regulation 262(1) of SEBI ICDR Regulations. Our Company has not appointed any monitoring agency for this Issue. However, as per Section 177 of the Companies Act, 2013, the Audit Committee of our Company, would be monitoring the utilization of the proceeds of the Issue and we shall submit a certificate of the statutory auditor for utilization of money raised through the public issue to exchange while filing the quarterly financial results, till the issue proceeds are fully utilized.

Our Board and Audit committee shall monitor the utilization of the net proceeds of the Issue. Our Company will disclose the utilization of the Net Proceeds under a separate head in our balance sheet along with the relevant details, for all such amounts that have not been utilized. Our Company will indicate investments, if any, of unutilized Net Proceeds in the balance sheet of our Company for the relevant financial years subsequent to the completion of the Issue.

Pursuant to SEBI LODR Regulations, our Company shall disclose to the Audit Committee of the Board of Directors, the uses and applications of the Net Proceeds. Our Company shall prepare a statement of funds utilized for purposes other than those stated in this Draft Prospectus and place it before the Audit Committee of the Board of Directors, as required under applicable law. Such disclosure shall be made only until such time that all the Net Proceeds have been utilized in full. The statement shall be certified by the statutory auditor of our Company. Furthermore, in accordance with the Regulation 32 of the SEBI LODR Regulations, our Company shall furnish to the Stock Exchange on a half yearly basis, a statement indicating (i) deviations, if any, in the utilization of the proceeds of the Issue from the Objects; and (ii) details of category wise variations in the utilization of the proceeds from the Issue from the Objects. This information will also be published in newspapers simultaneously with the interim or annual financial results, after placing the same before the Audit Committee of the Board of Directors

*This space has been left blank intentionally*

## SECTION VI: CAPITAL STRUCTURE

The table presents the current shareholding pattern of our Company as on the date of this Draft Red Herring Prospectus has been updated by removing (“\*”) mentioned in the table under the column “Number of equity shares held in dematerialized form (XIV)

*This space has been left blank intentionally*

## SECTION VII: PARTICULARS OF THE ISSUE

### OBJECT OF THE ISSUE

**The following information has been updated on page 116 of Draft Red Herring Prospectus:**

**The Existing Capacity of the company is as follows:**

*(Amount in ₹ lakhs except%)*

Product Family	Details	For the financial year ended		
		March 31, 2025	March 31, 2024	March 31, 2023
<b>Rapid Test</b>	Installed Capacity (Test)	30,00,000	30,00,000	500,000
	Production (Test)	25,16,250	21,94,325	3,97,475
	<b>Capacity Utilization (%)</b>	<b>83.88%</b>	<b>73.14%</b>	<b>79.50%</b>
<b>Reagents &amp; Other Consumables</b>	Installed Capacity (Ltr.)	3,000	1,000	-
	Production (Ltr.)	2,788	718	
	<b>Capacity Utilization (%)</b>	<b>92.93%</b>	<b>71.80%</b>	<b>0</b>
<b>Analyzers / Instruments</b>	Installed Capacity (Nos)	120	120	120
	Production (Nos)	91	70	89
	<b>Capacity Utilization (%)</b>	<b>75.83%</b>	<b>58.33%</b>	<b>74.17%</b>
<b>Culture Media</b>	Installed Capacity (Nos)	2,00,000	3,00,000	30,00,000
	Production (Nos)	149,600	51,000	839,850
	<b>Capacity Utilization (%)</b>	<b>74.80%</b>	<b>17%</b>	<b>28%</b>

**The Expected Capacity of the Company is as follows:**

S. No.	Product Group	Unit of Measurement	Capacity per Year*
1	Rapid Test	Capacity in Test	5,40,00,000
2	Reagents & Consumables	Capacity in Liters	61,200
3	Analysers/ Instruments	Capacity in Numbers	1440
4	Culture Media	Capacity in Numbers	5,04,000
5	Semi-Finished Products	Capacity in Numbers	36,000,000

\*Assuming 360 days in a year

**The rationale for increase in working capital of the company has been inserted on page 118 of Draft Red Herring Prospectus:**

The Company's working capital requirement has witnessed a consistent increase over the past three financial years, primarily driven by growth in revenue and the corresponding rise in trade receivables and inventory levels which can be understood from the below tables:

*Amount in ₹ lakhs, except %*

Particulars	31.03.2023	31.03.2024	31.03.2025
Revenue from Operations	1,092.06	1,625.51	2,888.95
Trade Receivables	180.72	242.16	889.01
<i>Trade Receivable as % of Revenue</i>	<i>16.55%</i>	<i>14.90%</i>	<i>30.77%</i>
Inventories	354.35	786.14	813.82
<i>Inventories as % of Revenue</i>	<i>32.45%</i>	<i>48.36%</i>	<i>28.17%</i>
Current Assets <sup>^1</sup>	663.64	1,197.78	1,844.68
<i>Current Assets as % of Revenue</i>	<i>60.77%</i>	<i>73.69%</i>	<i>63.85%</i>
Current Liabilities <sup>^2</sup>	322.62	597.86	904.80
<i>Current Liabilities as % of Revenue</i>	<i>29.54%</i>	<i>36.78%</i>	<i>31.32%</i>
<b>Working Capital</b>	<b>341.03</b>	<b>599.92</b>	<b>939.88</b>

Working Capital as % of Revenue	31.23%	36.91%	32.53%
---------------------------------	--------	--------	--------

<sup>^1</sup> (excluding cash & cash equivalent)

<sup>^2</sup> (excluding debts)

Amount in ₹ lakhs, except %

Particulars	31-Mar-23	31-Mar-24	31-Mar-25
<b>Sale of Goods</b>			
- Manufactured Goods	176.77	331.67	789.27
% Change yoy basis	-	87.63%	137.97%
- Traded Goods	915.29	1,293.84	2,089.06
% Change yoy basis	-	41.36%	61.46%
<b>Sale of Services</b>	-	-	10.63
% Change yoy basis	-	-	-
<b>Revenue from Operations</b>	<b>1,092.06</b>	<b>1,625.51</b>	<b>2,888.95</b>
% Change yoy basis	-	48.85%	77.73%

### 1. Revenue Growth Driving Higher Current Asset Base

Revenue from operations increased significantly from ₹1,092.06 lakh in FY 2022–23 to ₹1,625.51 lakh in FY 2023–24 (growth of ~48.85%), and further to ₹2,888.95 lakh in FY 2024–25 (growth of ~77.73%). This growth was largely driven by a significant rise in the sale of manufactured goods which increased by 87.63% in FY 2023–24 and 137.97% in FY 2024–25. The scale-up in business required proportionate increases in raw material procurement, production volumes, and finished goods inventory to support timely order fulfilment, resulting in higher working capital needs.

### 2. Increase in Trade Receivables due to Sales Growth and Credit Cycle

Trade receivables rose from ₹180.72 lakh in FY 2022–23 to ₹242.16 lakh in FY 2023–24 which represent growth of 34% in value terms. However, on a realisation-period basis, the collection cycle improved in FY 2023–24 compared to FY 2022–23.

The Trade Receivables further increased to ₹889.01 lakh in FY 2024–25 represented growth of ~267.12%, the reasons for higher trade receivable outstanding as on March 31, 2025 was the Sales made in the month of March 2025 was ₹ 457.68 Lakh of which majority part was outstanding as on financial year ended March 31, 2025.

The increase is attributable to higher sales volumes in both domestic and international markets. Additionally, the Trade Receivable increased due to higher sales volumes and stronger customer relationships, aligning with our strategy to grow while maintaining financial stability.

### 3. Inventory Build-up to Support Business Expansion

During the FY 2023-24, the increase in inventories by ₹431.78 lakhs as compared to FY 2022-23. The increase in inventory was primarily due to following reasons:

**Procurement of Trading goods:** The Company purchased trading goods from M/s Mindray Medical India Private Limited amounting to ₹ 295.75 lakhs (excluding GST) on March 28, 2024. This procurement was undertaken to support upcoming order/ business requirements and enabled the Company to avail quantity-based discounts and turnover-linked incentives offered by the supplier.

**Expansion of Product Portfolio:** During the financial year 2023-24, the Company obtained 31 new production licenses. Consequently, we initiated the procurement of raw materials and commenced production for these newly approved products, leading to an increase in inventory.

**Operational Scaling:** The Company has been scaling up its operations to meet growing market demand, which necessitated higher inventory levels to ensure seamless production and supply chain continuity.

### 4. Strategic Alignment with Growth Objectives



The increase in working capital is aligned with the Company's growth strategy to cater to a wider customer base, improve delivery timelines, and maintain competitive advantage through ready availability of products.

With expansion into new geographies and product lines, maintaining adequate receivables and inventories is critical for sustaining the momentum of business operations.

**Rationale for substantial increase in working capital requirement in estimated period.**

In the estimated period, there is an increase in our working capital requirements as we are expecting the completion of our new production facility by the end of December month and the commercial production will begin in the month of March – 2026. Therefore, the following reasons will affect our working capital requirements

- **Stock:** We will begin large-scale procurement of raw materials for production at a new manufacturing facility, in accordance with its production capacity and requirements. This will significantly increase our inventory of raw materials as well as semi-finished and finished goods.
- **Advance to suppliers:** The raw materials are procured against 100% advance payment. Hence, in the new production facility, a cycle of advances to suppliers will start for such materials.
- **Sundry Debtors:** With the increase in sales capacity from the new production unit, sundry debtors are expected to grow.

**The following lines has been inserted under basis of estimation of working capital table on page 118 of Draft Red Herring Prospectus:**

The details of the working capital requirement have been certified by the peer review auditor M/s Manish Pandey and associates dated July 18, 2025, bearing UDIN 25549996BOOECA7018.

*This space has been left blank intentionally*

## SECTION VIII – ABOUT THE COMPANY

### OUR BUSINESS

**The Brief details of B2B, B2C and B2G has been included on page 150 of Draft Red Herring Prospectus:**

#### **B2B (Business-to-Business)**

This segment includes sales to distributors and traders who purchase goods from the Issuer Company for the purpose of resale. These partners act as intermediaries, enabling wider market reach and distribution of our products to various regions and customer groups.

#### **B2C (Business-to-Customer)**

The B2C segment comprises direct sales to hospitals, diagnostic laboratories, and other healthcare facilities engaged in in-vitro diagnostics (IVD) testing. These customers are the ultimate end-users of our products, consuming them directly for patient care and diagnostic purposes.

#### **B2G (Business-to-Government)**

This segment covers direct supplies to government entities, public sector undertakings (PSUs), and other government-controlled organisations. These transactions are generally governed by tenders, rate contracts, or direct procurement processes.

**On page 158 of Draft Red Herring Prospectus, the write up on trading of goods has been inserted as follows:**

We are an authorised channel partner of Mindray Medical India Private Limited, engaged in the trading of advanced in-vitro diagnostic (IVD) solutions. Our product range covers a wide spectrum of goods used in the detection, diagnosis, and monitoring of diseases and medical conditions through the analysis of human samples such as blood.

Our offerings can be broadly categorised as follows:

#### **1. Reagents & Consumables**

Essential for conducting diagnostic tests, these products are consumed on a daily basis in laboratories and hospitals.

- Biochemistry Reagents – for liver function tests (LFT), kidney function tests (KFT), lipid profiles, glucose tests, etc.
- Haematology Reagents – for complete blood count (CBC), differential count, etc.
- Immunoassay Reagents – for detecting hormones, infectious diseases, and tumour markers.
- Consumables – cuvettes, pipette tips, test tubes, microplates, and filters.

#### **2. Diagnostic Instruments & Equipment**

Hardware and analysers that enable accurate and efficient IVD testing.

- **Automated Biochemistry Analysers** – fully or semi-automated systems.
- **Haematology Analysers** – 3-part or 5-part differential systems.

- **Immunoassay Analysers** – CLIA systems, ELISA readers and washers.
- **Molecular Diagnostic Instruments** – PCR machines, thermocyclers.
- **Microbiology Instruments** – incubators, autoclaves, colony counters.
- **Electrolyte Analyser** - used to measure the concentration of electrolytes in biological fluids such as blood, serum, plasma, or urine

**On page 158 of Draft Red Herring Prospectus, the following information has been inserted under Service head:**

Once the warranty period for a product has expired, customers have the option to enter into an Annual Maintenance Contract (AMC) or a Comprehensive Maintenance Contract (CMC) with the Company to ensure continued performance and reliability of their equipment.

These are our portfolio service available for all the interested customers for a duration of one year and can be extended up to three years based on the customer's requirements and budget.

AMC generally covers preventive maintenance services and labour charges, with the cost of spare parts billed separately.

CMC includes both preventive and corrective maintenance services, along with the cost of spare parts, providing complete service coverage.

Offering AMC and CMC options allows customers to minimize downtime and ensure uninterrupted operations of critical diagnostic equipment.

**On page 158 of Draft Red Herring Prospectus, the Branding of goods has been inserted as follows:**

The products manufactured by the Issuer Company are sold under the brand name “Avienbio”. The trading products procured by the Company from third-party manufacturers are marketed and sold under their respective original brand names as received.

**The below mentioned details have been included on page 190 of Draft Red Herring Prospectus: -**

Particulars	FY 2022-23	FY 2023-2024	FY 2024-2025
No. of Suppliers engaged-Trading	15	18	27
No. of Suppliers engaged-Manufacturing	39	45	53

**The Country and state wise raw material procurement has been inserted on page 206 of Draft Red Herring Prospectus:**

**Country-wise Procurement**

Country	FY 2022-23	%	FY 2023-24	%	FY 2024-25	%
China	5.66	5.18%	76.49	31.33%	66.38	22.47%
India	103.52	94.82%	167.65	68.67%	229.10	77.53%
<b>Total</b>	<b>109.17</b>	<b>100.00%</b>	<b>244.14</b>	<b>100.00%</b>	<b>295.48</b>	<b>100.00%</b>

### State-wise Procurement

State	FY 2022-23	%	FY 2023-24	%	FY 2024-25	%
Haryana	25.46	24.59%	39.46	23.54%	87.85	38.35%
Delhi	17.06	16.48%	51.03	30.44%	65.52	28.60%
Gujarat	10.09	9.74%	31.38	18.72%	39.94	17.44%
Punjab	18.30	17.68%	13.90	8.29%	18.66	8.14%
Maharashtra	6.01	5.81%	12.15	7.24%	6.86	2.99%
Uttar Pradesh	6.98	6.74%	6.47	3.86%	4.98	2.17%
Goa	1.73	1.67%	12.07	7.20%	3.65	1.59%
Himachal Pradesh	0.29	0.28%	0.88	0.52%	0.88	0.38%
Odisha	0.00	0.00%	0.00	0.00%	0.42	0.18%
Dadra & Nagar Haveli	0.00	0.00%	0.33	0.19%	0.35	0.15%
Chandigarh	17.60	17.00%	0.00	0.00%	0.00	0.00%
Noida	0.00	0.00%	0.00	0.00%	0.00	0.00%
<b>Total</b>	<b>103.52</b>	<b>100.00%</b>	<b>167.65</b>	<b>100.00%</b>	<b>229.10</b>	<b>100.00%</b>

*Note: The Amount is exclusive of Direct expenses*

**Details regarding the total number of customers during the past three financial years, along with the number of repeat customers, are included on page 215 of the Draft Red Herring Prospectus:**

Segment	Type	FY 2024-25	FY 2023-24	FY 2022-23
B2B	Total Customers	61	52	50
B2C		89	60	46
B2G		41	41	30
Export B2B		5	6	0
<b>Total</b>		<b>196</b>	<b>159</b>	<b>126</b>
B2B	Repeated Customers	21	26	6
B2C		34	23	12
B2G		20	6	5
Export B2B		3	0	0
<b>Total</b>		<b>78</b>	<b>55</b>	<b>23</b>

**Our Country wise bifurcation has been updated on page 216 of Draft Red Herring Prospectus:**

**Our country wise Export bifurcation is as follows:-**

*Amount in ₹ lakhs, except %*

Country	For the Financial Year ended					
	March 31, 2025	%*	March 31, 2024	%*	March 31, 2023	%*
Dubai	403.00	13.95%	-	-	-	-
Ethiopia	105.82	3.66%	10.03	0.62%	-	-
Ghana	-	-	0.54	0.03%	-	-
Nepal	-	-	4.42	0.27%	-	-
Somalia	10.41	0.36%	36.95	2.27%	-	-
Zambia	5.08	0.18%	7.24	0.45%	-	-

<b>Total</b>	<b>524.30</b>	<b>18.15%</b>	<b>59.18</b>	<b>3.64%</b>	-	-
--------------	---------------	---------------	--------------	--------------	---	---

*\*% of Revenue from operations*

**The Human Resource section mentioned on page 216 has been updated as follows:**

There are total of 66 employees on payroll inclusive of contract labour. Out of which 34 are permanent employees and 32 are contract labour. The detailed break-up of our employees is as under:

<b>Department</b>	<b>No. of Employees</b>
Procurement	2
R&D*	4
QC & QA	2
Production	25
Sales & Marketing	9
Service	4
Supply chain	11
Accounts	2
HR	1
CS & Compliance	1
CFO	1
Management	3
Office Admin	1
<b>Total</b>	<b>66</b>

<b>Designation</b>	<b>No. of Persons Employed</b>
Skilled Labors	30
Unskilled Labors	36
<b>Total</b>	<b>66</b>

*This space has been left blank intentionally*

## SECTION IX - FINANCIAL STATEMENTS

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF OPERATIONS

**The below mentioned Rationale has been included on page 271 after explanation to Net profit after tax:**

The Company's PAT margin increased from 8.83% in FY 2023–24 to 15.86% in FY 2024–25 on a consolidated basis. The key factors contributing to this improvement are as follows:

<i>Amount in ₹ lakhs, except %</i>				
<b>Particulars</b>	<b>31-Mar-25</b>	<b>% *</b>	<b>31-Mar-24</b>	<b>% *</b>
<b>Sale of Goods</b>				
Manufactured Goods	792.85	17.53%	353.08	14.73%
Traded Goods	3,717.30	82.18%	2,043.32	85.27%
Services	13.44	0.30%		0.00%
<b>Revenue from Operations</b>	<b>4,523.59</b>	<b>100.00%</b>	<b>2,396.40</b>	<b>100.00%</b>
Direct Costs	2,706.35	59.83%	1,558.77	65.05%
Employees Benefit Expenses	321.06	7.10%	201.92	8.43%
Other Expenses	355.19	7.85%	228.18	9.52%
<b>EBITDA</b>	<b>1,141.00</b>	<b>25.22%</b>	<b>407.52</b>	<b>17.01%</b>
<b>PAT<sup>#</sup></b>	<b>729.08</b>		<b>215.16</b>	
<b>PAT Margin %</b>	<b>15.86%</b>		<b>8.83%</b>	

*\*of Revenue from Operations; #PAT Margin has been calculated on Total Income.*

#### 1. Higher Contributions of Manufactured Goods

- Revenue from Manufactured Goods increased by 124.56%, from ₹353.08 lakh in FY 2023–24 to ₹792.85 lakh in FY 2024–25.
- The share of manufactured goods in total revenue increased from 14.73% to 17.53%, supported by the introduction of new products and an expansion in production capacity.
- Export sales of manufactured goods formed a greater share of this segment in FY 2024–25. Export markets generally offer better pricing, reduced price competition, and higher realisations compared to domestic trading activities, leading to enhanced gross margins.

#### 2. Improved Cost Efficiency

- Direct Costs as a percentage of revenue reduced from 65.05% in FY 2023–24 to 59.83% in FY 2024–25, driven by:
  - Better procurement planning and bulk sourcing of raw materials.
  - Optimisation of supply chain.
  - Higher in-house manufacturing, which reduced dependence on third-party suppliers for certain products.
- Employee Benefit Expenses declined from 8.43% to 7.10% of revenue, primarily due to productivity improvements, efficient workforce deployment, and the leveraging of existing talent without proportionate additions in headcount.

- Other Expenses reduced from 9.52% to 7.85% of revenue, reflecting disciplined cost management in areas such as travel, legal, and administrative expenses and promotion expenses.

### **3. Scale and Operating Leverage**

- Total revenue grew by **1.89 times**, from ₹2,396.40 lakh in FY 2023–24 to ₹4,523.59 lakh in FY 2024–25.
- Many fixed overheads (e.g., rent, salaries of key management, professional fees) remained relatively stable in absolute terms. Spreading these costs over a significantly higher revenue base resulted in improved per-unit cost efficiency, thereby enhancing EBITDA and PAT margins.

*This space has been left blank intentionally*

## SECTION X: LEGAL AND OTHER INFORMATION

### OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

**The dates of hearing pertaining to the cases have been updated in this chapter.**

**(a) Criminal proceedings filed by the Company**

**(i) Avience Biomedicals Private Limited vs Rita Singh (Proprietor of Medicare Diagnostic Services)**

**Court Name:** Chief Metropolitan Magistrate, New Delhi, Patiala House Court

**Case no:** CC NI 29590/2023

**Facts of the case:** The Defendant had purchased goods from the Company on various instances for which the Defendant was issued invoice/ bills dated 11/03/2023 invoice no. ABM/22-23/724, Invoice dated 25/03/2023 Invoice no. ABM/22-23/783, invoice dated 29/04/2023 invoice no. ABM/23,24/89 and Invoice dated 13/05/2023 INVOICE NO.ABM/23-24/153. As per the ledger account maintained by the Company, an amount Rs. 06,02,100/- (Rupee Six lakh two thousand one hundred) is pending upon the Defendant and the Defendant had made assurance to make the payments within 30 days as agreed upon with the Company. Subsequently, the Defendant issued some cheques, and when they were presented by the Company, the said 8 cheque/s were dishonoured, hence the Company filed a complaint against the Defendant.

**Brief of the case:** The case has been filed for recovery of an amount of Rs. 6,02,100/- from the accused which was due to the complainant.

**Current Stage:** Fixed for verification of address of accused

**Next date of hearing:** 13/01/2026

**(ii) Avience Biomedicals Private Limited vs Surabhi Rani (Proprietor of Shree Bala Ji Trader)**

**Court Name:** Chief Metropolitan Magistrate, New Delhi, Patiala House Court

**Case no:** CC NI 25022/2024

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. ABM/23-24/578 (E-WAY BILL NO. 771374846898) dated 13/10/2023 of Rs. 1,10,000/- (One Lak Ten Thousand Only) including IGST and the defendant made assurance to make the payments within 30 days as agreed but the defendant has not cleared its entire liability till date towards the Company.

**Brief of the case:** The case is filed due to default in making payments to the Plaintiff for the goods availed by the defendant.

**Current Stage:** Summons Stage

**Next date of hearing:** 30/04/2026



(iii) **Avience Biomedicals Private Limited vs M/s Unique Healthcare and Ors.**

**Court Name:** Chief Metropolitan Magistrate, New Delhi, Patiala House Court

**Case no:** CC NI 2019/2024

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the company, upon which the defendant was issued invoice no. ABM/23-24/349 (E-WAY BILL NO. 781351024564) dated 08/07/2023 of Rs. 9390/- (Nine Thousand Three Hundred Ninety Only) including IGST and the defendant assured that the payments will be made within 30 days as agreed but defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** The case is filed due to default in making payments to the Plaintiff for the goods availed by the defendant.

**Current Stage:** Summons Stage

**Next date of hearing:** 10/02/2026

(iv) **Avience Biomedicals Private Limited vs Parveen Pahwa (Proprietor of D and D Traders)**

**Court Name:** Chief Metropolitan Magistrate, New Delhi, Patiala House Court

**Case no:** CC NI 25024/2024

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. AVM/23-24/165 (E-WAY BILL NO. 411406729516) dated 25/01/2024 of Rs. 1,61,700/- (One Lakh Sixty One Thousand Seven Hundred Only) including IGST and the defendant assured that the payments would be made within 30 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** The case is filed due to the default of making payments to the Plaintiff for the goods availed by the defendant.

**Current Stage:** Summons Stage

**Next date of hearing:** 30/04/2026

(v) **Avience Biomedicals Private Limited vs Ajay Shukla Prop. of M/S S S Enterprises**

**Court Name:** PATIALA HOUSE COURT

**Case no:** CC NI ACT 60091/2024

**Facts of the case:** The Defendant had purchased goods from the Company on various instances for which the Defendant was issued invoice/ bills dated 07/03/2023 invoice no. ABM/22-23/700, Invoice dated 27/03/2023 Invoice no. ABM/22-23/786, invoice dated 29/04/2023 invoice no. ABM/23-24/9. As per the ledger account maintained by the Company, an amount Rs. 1,90,449/- (Rupee One lakh Ninety thousand Four hundred Forty Nine) is pending upon the Defendant and

the Defendant had made assurance to make the payments within 30 days as agreed upon with the Company. Subsequently, the Defendant issued some cheques, and when they were presented by the Company, the said 9 cheque/s were dishonoured, hence the Company filed a complaint against the Defendant.

**Brief of the case:** Complaint U/S 138/141 NI Act Criminal Complaint was filled for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at summons stage

**Current Stage:** Summons Stage

**Next date of hearing:** 16/02/2026

(vi) **Avience Biomedicals Private Limited vs Ankush Choudhary Prop. Of care Bio Medicals**

**Court Name:** Tis Hazari

**Case no:** CC NI ACT 6563/2022

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. ABM/00188 dated 15/02/2022 of Rs. 60,000/- ( Sixty Thousand Only) including IGST and the defendant assured that the payments would be made within 45 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at a stage of fixed for verification of address of accused.

**Current Stage:** Fixed for verification of address of accused.

**Next date of hearing:** 17/10/2025

(i) **Avience Biomedicals Private Limited vs Testocare Healthcare Pvt. Ltd.**

**Court Name:** Patiala House Court

**Case no:** CC NI ACT 26166/2025

**Facts of the case:** The Defendant had purchased goods from the Company on various instances for which the Defendant was issued invoice/ bills dated 30/09/2024 invoice no. ABMD/24-25/1186, Invoice dated 03/10/2024 Invoice no. ABMD/24-25/1201, invoice dated 05/11/2024 invoice no. ABMD/24-25/1433, invoice dated 13/11/2024 invoice no. ABMD/24-25/1545, invoice dated 13/11/2024 invoice no. ABMD/24-25/1546, invoice dated 16/11/2024 invoice no. ABMD/24-25/1571, invoice dated 19/11/2024 invoice no. ABMD/24-25/1594, invoice dated 19/11/2024 invoice no. ABMD/24-25/1595, invoice dated 19/11/2024 invoice no. ABMD/24-25/1596, invoice dated 19/11/2024 invoice no. ABMD/24-25/1597, invoice dated 20/11/2024 invoice no. ABMD/24-25/1603,

invoice dated 23/11/2024 invoice no. ABMD/24-25/1628, invoice dated 25/12/2024 invoice no. ABMD/24-25/1834, invoice dated 31/12/2024 invoice no. ABMD/24-25/1878, invoice dated 08/01/2025 invoice no. ABMD/24-25/1928, invoice dated 23/01/2025 invoice no. ABMD/24-25/2035, invoice dated 23/01/2025 invoice no. ABMD/24-25/2036, invoice dated 23/01/2025 invoice no. ABMD/24-25/2037, invoice dated 08/02/2025 invoice no. ABMD/24-25/2175, invoice dated 08/02/2025 invoice no. ABMD/24-25/2176, invoice dated 18/02/2025 invoice no. ABMD/24-25/2268 . As per the ledger account maintained by the Company, an amount Rs. 40,37,340/- (Rupee Fourty lakh Thirty Seven thousand Three hundred Fourty) is pending upon the Defendant and the Defendant had made assurance to make the payments within 45 days as agreed upon with the Company. Subsequently, the Defendant issued some cheques, and when they were presented by the Company, the said 1 cheque/s were dishonoured, hence the Company filed a complaint against the Defendant.

**Brief of the case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at consideration stage.

**Current Stage:** Consideration

**Next date of hearing:** 30/10/2025

(ii) **Avience Biomedicals Private Limited vs Anvika Enterprises**

**Court Name:** Patiala House Court

**Case no:** CC NI ACT /16326/2025

**Facts of the case:** The Defendant had purchased goods from the Company on various instances for which the Defendant was issued invoice/ bills dated 09/01/2023 invoice no. ABM/22-23/538, Invoice dated 21/03/2023 Invoice no. ABM/22-23/758, invoice dated 30/03/2023 invoice no. ABM/22-23/800, invoice dated 03/04/2023 invoice no. ABM/23-24/3, invoice dated 24/04/2023 invoice no. ABM/23-24/66, invoice dated 29/04/2023 invoice no. ABM/23-24/87, invoice dated 10/07/2023 invoice no. ABM/23-24/355, invoice dated 11/08/2023 invoice no. ABM/23-24/505, invoice dated 02/09/2024 invoice no. ABM/23-24/614, invoice dated 26/10/2023 invoice no. ABM/23-24/922, invoice dated 31/10/2023 invoice no. ABM/23-24/922, invoice dated 20/12/2023 invoice no. ABM/23-24/1203, invoice dated 05/02/2024 invoice no. ABM/23-24/1374, invoice dated 27/02/2024 invoice no. ABM/23-24/1480, invoice dated 02/05/2024 invoice no. ABM/24-25/175 . As per the ledger account maintained by the Company, an amount Rs. 8,18,956/- (Rupee Eight lakh Eighteen thousand Nine hundred Fifty Six) is pending upon the Defendant and the Defendant had made assurance to make the payments within 30 days as agreed upon with the Company. Subsequently, the Defendant issued some cheques, and when they were presented by the Company, the said 1 cheque/s were dishonoured, hence the Company filed a complaint against the Defendant.

**Brief of the case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at consideration stage.

**Current Stage:** Consideration

**Next date of hearing: 10/10/2025**

**(iii) Avience Biomedicals Private Limited vs Apexcare Medigenix Private Ltd**

**Court Name: Patiala Court**

**Case no: CC NI ACT /28071/2025**

**Facts of the case:** The Defendant had purchased goods from the Company on various instances for which the Defendant was issued invoice/ bills dated 11/10/2024 invoice no. ABMN/24-25/194, Invoice dated 27/03/2023. As per the ledger account maintained by the Company, an amount Rs. 5,47,281/- (Rupee Five lakh Fourty Seven thousand Two hundred Eighty One is pending upon the Defendant and the Defendant had made assurance to make the payments within 45 days as agreed upon with the Company. Subsequently, the Defendant issued some cheques, and when they were presented by the Company, the said 1 cheque/s were dishonoured, hence the Company filed a complaint against the Defendant.

**Brief of the case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at consideration stage.

**Current Stage: Consideration**

**Next date of hearing: 02/02/2026**

**(iv) Avience Biomedicals Private Limited vs Alol D Mart**

**Court Name: Patiala House Court**

**Case no: CC NI ACT /8168/2025**

**Facts of the case:** The Defendant had purchased goods from the Company on various instances for which the Defendant was issued invoice/ bills dated 16/09/2024 invoice no. ABMD/24-24/1081, Invoice dated 20/09/2024 Invoice no. ABMD/24-25/1104, invoice dated 27/09/2024 invoice no. ABMD/24-25/1155. As per the ledger account maintained by the Company, an amount Rs. 2,59,063/- (Rupee Two lakh Fifty Nine thousand Sixty Three) is pending upon the Defendant and the Defendant had made assurance to make the payments within 45 days as agreed upon with the Company. Subsequently, the Defendant issued some cheques, and when they were presented by the Company, the said 1 cheque/s were dishonoured, hence the Company filed a complaint against the Defendant.

**Brief of the case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at consideration stage.

**Current Stage: Consideration**

**Next date of hearing:** 28/11/2025

**(b) Other pending material litigations against the Company**

As on the date of this Draft Red Herring Prospectus, there are no outstanding material litigation initiated against the Company except as stated below:

**(c) Other pending material litigations filed by the Company**

**(i) Avience Biomedicals Private Limited vs Mandeep (Pari Distributor)**

**Court Name:** Dwarka Court

**Case no:** CS SCJ 307/2024

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. ABM/22-23/657 dated 23/02/2023 of Rs. 61,950/- ( Sixty One Thousand Nine Hundred Fifty Only) including IGST and the defendant assured that the payments would be made within 45 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage and dasti is issued by the hon'ble court to the defendant.

**Current Stage:** Summons

**Next date of hearing:** 10/11/2025

**(ii) Avience Biomedicals Private Limited vs Medimudra Private Limited**

**Court Name:** Dwarka Court

**Case no:** CC NI ACT /439/2025

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. ABM/23-24/165 dated 19/05/2023 of Rs. 35,000/- ( Thirty Five Thousand Only) including IGST and the defendant assured that the payments would be made within 45 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage and dasti is issued by the hon'ble court to the defendant.

**Current Stage:** Summons

**Next date of hearing:**08/10/2025

**(iii) Avience Biomedicals Private Limited vs Alpha Invitro Diagnostics Pvt Ltd.**

**Court Name:** Dwarka Court

**Case no:** CS (COMM) 361/2025

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. ABM/22-23/438 dated 23/11/2022, invoice no. ABM/22-23/478 dated 14/12/2022, invoice no. ABM/22-23/558 dated 12/01/2023, invoice no. ABM/22-23/562 dated 12/01/2023, invoice no. ABM/22-23/600 dated 01/02/2023, invoice no. ABM/22-23/646 dated 22/02/2023, invoice no. ABM/22-23/708 dated 09/03/2023, invoice no. ABM/22-23/707 dated 09/03/2023, invoice no. ABM/22-23/718 dated 10/03/2023, invoice no. ABM/22-23/755 dated 20/03/2023, invoice no. ABM/22-23/801 dated 31/03/2023, invoice no. ABM/23-24/2 dated 03/04/2023, invoice no. ABM/23-24/51 dated 21/04/2023, invoice no. ABM/23-24/73 dated 27/04/2023, invoice no. ABM/22-23/166 dated 19/05/2023 of Rs. 6,01,184/- ( Six Lakh One Thousand One Hundred Eighty Four Only) including IGST and the defendant assured that the payments would be made within 45 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage and dasti is issued by the hon'ble court to the defendant.

**Current Stage: Summons**

**Next date of hearing: 06/10/2025**

(iv) **Avience Biomedicals Private Limited vs Expert Healthcare & Diagnostics Pvt Ltd**

**Court Name: Dwarka Court**

**Case no:** CS(COMM) 362/2025

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. ABM/22-23/798 dated 29/03/2023, invoice no. ABM/23-24/96 dated 01/05/2023, invoice no. ABM/23-24/182 dated 25/05/2023, invoice no. ABM/23-24/293 dated 24/06/2023, invoice no. ABM/23-24/412 dated 24/07/2023, of Rs. 4,29,321/- ( Four Lakh Twenty Nine Thousand Three Hundred Twenty One Only) including IGST and the defendant assured that the payments would be made within 45 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage and dasti is issued by the hon'ble court to the defendant.

**Current Stage: Summons**

**Next date of hearing: 06/10/2025**

(v) **Avience Biomedicals Private Limited vs M.S. Scientific & Chemicals**

**Court Name: Dwarka Court**

**Case no:** N/A

**Facts of the case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. AVM/23-24/23 dated 09/05/2023, invoice no. AVM/23-24/126 dated 06/10/2023, invoice no. ABM/23-24/300 dated 27/06/2023, invoice no. ABM/23-24/603 dated 01/09/2023, invoice no. ABM/23-24/805 dated 06/10/2023, invoice no. ABM/23-24/807 dated 06/10/2023, invoice no. ABM/23-24/808 dated 06/10/2023 of Rs. 7,43,195/- (Seven Lakh Fourty Three Thousand One Hundred Ninety Five Only) including IGST and the defendant assured that the payments would be made within 45 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage and dasti is issued by the hon'ble court to the defendant.

**Current Stage:** Summons

**Next date of hearing:** 06/10/2025

## **LITIGATIONS INVOLVING THE PROMOTERS & DIRECTORS OF THE COMPANY**

### **(a) Criminal proceedings against the Promoters & Directors of the Company**

As on the date of this Draft Red Herring Prospectus, except as stated below there are no outstanding criminal proceedings initiated against the Promoters & Directors of the Company.

#### **(i) M/S Parekh Integrated Service Private Limited vs Dharam Deo Choudhary, Ram Nagina Choudhary, Kapil Deo Choudhary and DR Meditech Surgicals & Diagnostics**

**Court Name:** Metropolitan Magistrate's 44<sup>th</sup> Court at Andheri, Mumbai

**Case no:** CC No. 817/SS/2021

**Facts of the case:** M/s Parekh Integrated Services Pvt Ltd. was engaged by Avience Biomedicals, on commitment to give opportunity of sale to M/s Parekh through its agents. The Complainant alleged that the materials supplied by Avience were not as per the required quality standards resulting in the Complainant being unable to further distribute the materials purchased from Avience. In order to discharge its liability towards M/s Parekh, Avience had issued a cheque dated 19/11/2020 for INR 11,25,092/- only which was dishonoured due to insufficient funds. After issuing multiple demand notices, Avience had not cleared the outstanding amount and hence, the Complainant initiated proceedings against Avience under Section 138 of the Negotiable Instruments Act, 1981.

**Brief of the case:** The Plaintiff denied to take the expired material back and Avience therefore did not pay for the materials due to them not being as per the required quality standards.

**Current Stage:** Not Heard Cases

**Next date of hearing:** Disposed (Uncontested – Lok Adalat) Case stands disposed of in Lok Adalat

## **D. LITIGATION INVOLVING KEY MANAGERIAL PERSONNEL**

### **Cases filed against Key Managerial Personnel**

#### **a. Criminal Proceedings:**

As on the date of this DD Report, there are no Criminal Proceedings against the Key Managerial Personnel.

#### **b. Actions taken by Statutory/Regulatory Authorities**

As on the date of this DD Report, there are no actions taken by statutory regulatory authorities against the Key Managerial Personnel.

#### **c. Tax Proceedings**

As on the date of this DD Report, there are no Tax Proceedings against the Key Managerial Personnel.

#### **d. Disciplinary action taken by SEBI or Stock Exchanges**

As on the date of this DD Report, no disciplinary action by the SEBI or Stock Exchanges initiated against the Key Managerial Personnel.

#### **e. Other Material Litigations**

Vehicle Challan:

Registration No.- TC/323868/2025; Challan No.- DL20707241125185456; Challan Date- 25-11-2024; Name- Saurabh Verma; District Name- South West Delhi

### **2. Cases filed by Key Managerial Personnel**

#### **a. Criminal Proceeding**

As on the date of this DD Report, there are no outstanding Criminal Proceedings initiated by the Key Managerial Personnel.

#### **b. Tax Proceedings**

As on the date of this DD Report, no outstanding tax proceedings initiated by the Key Managerial Personnel.

#### **c. Other Material Litigations**

As on the date of this DD Report, there are no other material litigations initiated by the Key Managerial Personnel.

### **(a) Criminal proceedings filed by the group company of the Company**

#### **(i) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus RAJESH SRIVASTVA PROP SIDHI ENTERPRISES**

**Court Name:** Dwarka Court, New Delhi

**Case Number:** CC NI ACT/21846/2021

**Facts of the Case:** Complaint us 138/141 NI act was filled for dishonour of cheque. The cheque was issued by the accused for the payment against the goods supplied to the accused by the Company. However, the cheque was dishonoured and hence the present suit for recovery of Rs 89,033/- along with interest.

**Brief of the Case:** Dishonour of cheque issued against goods supplied by the Company

**Case Status:** Purpose



**Next date of hearing:** 24/02/2026

**(ii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus RANJEET SINGH PROP INDIA DIAGNOSTIC ENTERPRISES**

**Court Name:** Dwarka Court, New Delhi

**Case Number:** CC NI ACT/21124/2021

**Facts of the Case:** Complaint us 138/141 NI act was filled for dishonour of cheque. The cheque was issued by the accused for the payment against the goods supplied to the accused by the Company. However, the cheque was dishonoured and hence the present suit for recovery of Rs 8,92,826/- along with interest. The matter was referred to the mediation cell on 22/10/2024 and the matter is fixed for a report on compromise.

**Brief of the Case:** Dishonour of cheque issued against goods supplied by the Company

**Case Status:** Purpose

**Next date of hearing:** 21/08/2025

**(iii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus RANJEET SINGH**

**Court Name:** Dwarka Court, New Delhi

**Case Number:** CC NI ACT/1908/2022

**Facts of the Case:** Complaint us 138/141 Ni act was filled for dishonour of cheque. The cheque was issued by the accused for the payment against the goods supplied to the accused by the Company. However, the cheque was dishonoured and hence the present suit for recovery of Rs 8,92,826/- along with interest. The matter was referred to the mediation cell on 22/10/2024 and the matter is fixed for a report on compromise.

**Brief of the Case:** Dishonour of cheque issued against goods supplied by the Company

**Case Status:** Purpose

**Next date of hearing:** 25/09/2025

**(iv) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus 360 DIAGNOSTIC AND HEALTH SERVICES PVT LTD**

**Court Name:** Dwarka Court, New Delhi

**Case Number:** CS/SCJ/2003/2024

**Facts of the Case:** Civil suit for recovery of money under the Civil Procedure Code was filed by the Company. The Company had supplied goods to the respondent but the respondent defaulted in making payments of Rs 89,773/-. Summons were issued to the defendant by the Hon'ble court on 24/10/2024.

**Brief of the Case:** Suit for recovery of money

**Case Status:** Purpose

**Next date of hearing:** 16/10/2025

(v) **DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus ORBIT IMAGING AND PATH LAB PVT LTD**

**Court Name:** Dwarka Court, New Delhi

**Case Number:** CS/SCJ/2002/2024

**Facts of the Case:** Civil suit for recovery of money under the Civil Procedure Code was filed by the Company. The Company had supplied goods to the respondent but the respondent defaulted in making payments of Rs 1,94,813/-. Summons were issued to the defendant by the Hon'ble court on 24/10/2024.

**Brief of the Case:** Suit for recovery of money

**Case Status:** Purpose

**Next date of hearing:** 14/10/2025

(vi) **DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus BHUPENDER PROP. OF OM PATH LAB**

**Court Name:** Dwarka Court

**Case Number:** CR No. 51/2020 (89/2020)

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTDG/17-18/4970 dated 27/11/2017, of Rs.20,000/- ( Twenty Thousand Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Revision petition was filed by Dr Meditech as the complaint was dismissed for non prosecution. Revision petition CN NO 51/220 Trial court Had notice that the complainant/petitioner not present before the trial court. The counsel son was not well hence he could not appear ,hence petition allowed and petition disposed of and complaint restored vide order dated 25/09/2020

**Case Status:** Disposed off

(vii) **DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus ALPHA INVITRO DIAGNOSTICS LIMITED**

**Court Name:** Dwarka Court, New Delhi

**Case Number:** CS (COMM) 297/2025

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/22-23/3794 dated 02/08/2022, invoice no. MTD/22-23/3784 dated 02/08/2022, invoice no. MTD/22-23/4300 dated 19/08/2022, invoice no. MTD/22-23/4508 dated 24/08/2022, invoice no. MTD/22-23/4493 dated 25/08/2022, invoice no. MTD/22-23/4656

dated 30/08/2022, invoice no. MTD/22-23/5673 dated 03/10/2022, invoice no. MTD/22-23/5872 dated 10/10/2022, invoice no. MTD/22-23/5912 dated 12/10/2022, invoice no. MTD/22-23/6009 dated 14/10/2022, invoice no. MTD/22-23/6057 dated 18/10/2022, invoice no. MTD/22-23/6047 dated 18/10/2022, invoice no. MTD/22-23/6328 dated 29/10/2022, invoice no. MTD/22-23/6444 dated 03/11/2022, invoice no. MTD/22-23/6539 dated 05/11/2022, invoice no. MTD/22-23/6594 dated 07/11/2022, invoice no. MTD/22-23/6691 dated 11/11/2022, invoice no. MTD/22-23/6776 dated 14/11/2022, invoice no. MTD/22-23/6953 dated 22/11/2022, invoice no. MTD/22-23/6999 dated 24/11/2022, invoice no. MTD/22-23/7176 dated 01/12/2022, invoice no. MTD/22-23/7200 dated 02/12/2022, invoice no. MTD/22-23/7254 dated 05/12/2022, invoice no. MTD/22-23/7290 dated 06/12/2022, invoice no. MTD/22-23/7382 dated 10/12/2022, invoice no. MTD/22-23/7615 dated 22/12/2022, invoice no. MTD/22-23/7672 dated 24/12/2022, invoice no. MTD/22-23/8096 dated 12/01/2023, invoice no. MTD/22-23/8293 dated 20/01/2023, invoice no. MTD/22-23/9540 dated 14/03/2023, invoice no. MTD/23-24/01426 dated 30/05/2023 of Rs. 4,60,958/- (Four Lakh Sixty Thousand Nine Hundred Fifty Eight Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Plaintiff company has filed civil (commercial) suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage.

**Case Status:** Summons

**Next date of hearing:** 23/09/2025

**(viii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus METRO UMKAL HOSPITAL AND HEART INSTITUTE AND ANR**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ No. 566/2020

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued of Various invoices, of Rs. 1,52,065/- (One Lakh Fifty Two Thousand Sixty Five Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at cross examination stage of PW-1.

**Case Status:** Cross examination of PW-1

**Next date of hearing:** 06/11/2025

**(ix) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus NITESH ARORA PROP. OF V TRAVEL EXPERTZ**

**Court Name:** Dwarka Court

**Case Number: CC NO. 8503/2020**

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued of invoices, of Rs.55,000/- (Fifty Five Thousand Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at a stage of fixed for verification of address of accused.

**Case Status:** Verification of address of accused

**Next date of hearing:** 01-11-2025 (fresh summons issued to accused on 17/07/2025)

**(x) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus NEUBERG DIAGNOSTICS PVT. LTD.**

**Court Name: Dwarka Court**

**Case Number: CS (COMM) 295/2025**

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued of Various invoices, of Rs. 4,84,898/- (Four Lakh Eighty Four Thousand Eight Hundred Ninety Eight Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Plaintiff company has filed civil (commercial) suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage.

**Case Status: Summons**

**Next date of hearing: 23/09/2025**

**(xi) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus PATHCORP LABS PVT. LTD.**

**Court Name: Dwarka Court**

**Case Number: CS SCJ 327/2025**

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/22-23/812 dated 29/04/2022, invoice no. MTD/22-23/1006 dated 06/05/2022, invoice no. MTD/22-23/1650 dated 27/05/2022, invoice no. MTD/22-23/4667 dated 30/08/2022, invoice no. MTD/22-23/4666 dated 30/08/2022, invoice no. MTD/22-23/7518 dated 17/12/2022, of Rs. 1,35,470/- (One Lakh Thirty Five Thousand Four Hundred Seventy Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage.

**Case Status:** Summons

**Next date of hearing:** 17/10/2025

**(xii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus SERACUE LABS PVT. LTD.**

**Court Name:** Dwarka Court

**Case Number:** CS DJ ADJ 212/2020

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/15-16/6975 dated 06/01/2016, invoice no. MTD/15-16/6976 dated 06/01/2016, invoice no. MTD/15-16/6977 dated 06/01/2016, invoice no. MTD/15-16/6988 dated 07/01/2016, invoice no. MTD/15-16/6994 dated 07/01/2016, invoice no. MTD/15-16/7038 dated 08/01/2016, invoice no. MTD/15-16/7131 dated 13/01/2016, invoice no. MTD/15-16/7264 dated 18/01/2016, invoice no. MTD/15-16/7265 dated 18/01/2016, invoice no. MTD/15-16/7366 dated 22/01/2016, invoice no. MTD/15-16/7367 dated 22/01/2016, invoice no. MTD/15-16/7374 dated 22/01/2016, invoice no. MTD/15-16/7391 dated 23/01/2016, invoice no. MTD/15-16/7460 dated 28/01/2016, invoice no. MTD/15-16/7529 dated 30/01/2016, invoice no. MTD/15-16/7590 dated 02/02/2016, invoice no. MTD/15-16/7591 dated 02/02/2016, invoice no. MTD/15-16/7592 dated 02/02/2016, invoice no. MTD/15-16/7593 dated 02/02/2016, invoice no. MTD/15-16/7632 dated 03/02/2016, invoice no. MTD/15-16/7696 dated 05/02/2016, invoice no. MTD/15-16/7698 dated 05/02/2016, invoice no. MTD/15-16/7724 dated 06/02/2016, invoice no. MTD/15-16/7741 dated 06/02/2016, invoice no. MTD/16-17/2906 dated 26/07/2016, invoice no. MTD/16-17/2907 dated 26/07/2016, invoice no. MTD/16-17/2908 dated 26/07/2016 of Rs. 3,14,493/- (Three Lakh Fourteen Thousand Four Hundred Ninety Three Only) including VAT and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at cross examination stage of PW-1.

**Case Status:** Disposed Of

**(xiii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus EXPERT HEALTHCARE AND DIAGNOSTICS PVT. LTD.**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ 328/2025

**Facts of the Case:** The defendant purchased number of medical and lab

instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/22-23/8286 dated 20/01/2023, invoice no. MTD/22-23/8384 dated 25/01/2023, invoice no. MTD/22-23/8413 dated 27/01/2023, invoice no. MTD/22-23/8455 dated 30/01/2023, invoice no. MTD/22-23/8795 dated 11/02/2023, invoice no. MTD/22-23/8884 dated 15/02/2023, invoice no. MTD/22-23/8972 dated 20/02/2023, invoice no. MTD/22-23/9031 dated 22/02/2023, invoice no. MTD/22-23/9492 dated 11/03/2023, invoice no. MTD/22-23/9539 dated 14/03/2023, invoice no. MTD/22-23/9652 dated 18/03/2023, invoice no. MTD/22-23/9875 dated 28/03/2023, invoice no. MTD/22-23/9954 dated 31/03/2023, invoice no. MTD/23-24/0422 dated 18/04/2023, invoice no. MTD/23-24/0462 dated 19/04/2023, invoice no. MTD/23-24/0662 dated 26/04/2023, invoice no. MTD/23-24/0654 dated 27/04/2023, invoice no. MTD/23-24/0686 dated 28/04/2023, invoice no. MTD/23-24/0750 dated 01/05/2023, invoice no. MTD/23-24/0762 dated 02/05/2023, invoice no. MTD/23-24/01328 dated 25/05/2023, invoice no. MTD/23-24/01367 dated 26/05/2023, invoice no. MTD/23-24/01829 dated 14/06/2023, invoice no. MTD/23-24/01927 dated 17/06/2023, invoice no. MTD/23-24/01989 dated 21/06/2023, invoice no. MTD/23-24/02066 dated 24/06/2023 of Rs.1,34,530/- (One Lakh Thirty Four Thousand Five Hundred Thirty Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Complaint U/S 138/141 NI Act Criminal Complaint was filed for Dishonour of cheque. The cheque was issued by the accused for the payment against the good supplied to the accused however the cheque was dishonoured and present the same as per report. The matter is at a stage of fixed for verification of address of accused.

**Case Status:** Fixed for verification of address of accused

**Next date of hearing:** 30/10/2025

**(xiv) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus ZOHAN LABS**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ 379/2025

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/22-23/812 dated 29/04/2022, invoice no. MTD/22-23/1006 dated 06/05/2022, invoice no. MTD/22-23/1650 dated 27/05/2022, invoice no. MTD/22-23/4667 dated 30/08/2022, invoice no. MTD/22-23/4666 dated 30/08/2022, invoice no. MTD/22-23/7518 dated 17/12/2022, of Rs. 1,35,470/- (One Lakh Thirty Five Thousand Four Hundred Seventy Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Plaintiff company has filed civil suit for recovery of money under CPC as the plaintiff has supplied the good to the defendant however the defendant has not made the payment. This matter is at summons stage.

**Case Status:** Summons

**Next date of hearing:** 18/11/2025

**(xv) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus BIOGENE DIAGNOSTIC & SURGICAL**

**Court Name:** Dwarka Court

**Case Number:** EX CIVIL/1295/2018

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/16-17/T0580 dated 13/08/2016, invoice no. MTD/16-17/T0584 dated 16/08/2016, invoice no. MTD/16-17/T0585 dated 16/08/2016, invoice no. MTD/16-17/T0651 dated 25/08/2016, invoice no. MTD/16-17/T0653 dated 26/08/2016, invoice no. MTD/16-17/T0660 dated 27/08/2016, of Rs. 1,73,619/- (One Lakh Seventy Three Thousand Six Hundred Nineteen Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Meditech filed recovery suit and decree passed in Meditech's favour. Thereafter Meditech filed execution of decree and transfer certificate received and now to be filed where the defendant is working or residing.

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** Disposed

**(xvi) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus HR DIAGNOSTICS**

**Court Name:** Dwarka Court, Delhi

**Case Number:** CS SCJ 2119/2020

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/16-17/09340 dated 23/03/2017, invoice no. MTD/16-17/09452 dated 27/03/2017, invoice no. MTD/16-17/9470 dated 28/03/2017, invoice no. MTD/16-17/09580 dated 31/03/2017, invoice no. MTD/17-18/0569 dated 24/04/2017, invoice no. MTD/17-18/607 dated 25/04/2017, invoice no. MTD/17-18/1222 dated 17/05/2017, invoice no. MTD/17-18/1223 dated 17/05/2017, invoice no. MTD/17-18/2267 dated 26/06/2017 of Rs. 1,48,240/- (One Lakh Forty Eight Thousand Two Hundred Forty Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Decree passed on 28/11/2022 in Meditech's favour and execution to be filed from the court of senior civil judge South West Delhi.

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** Disposed

**(xvii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus GOLD FIELD HOSPITAL & RESEARCH CENTRE**

**Court Name:** Dwarka Court

**Case Number:** CS DJ SDJ/517897/16

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued of Various invoices, of Rs. 8,14,867/- (Eight Lakh Fourteen Thousand Eight Hundred Sixty Seven Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Filed recovery suit and decree passed in Meditech's favour

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** Disposed

**(xviii) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus OM PREMIA HOSPITAL**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ/923/2018

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/15-16/004197 dated 19/09/2015, invoice no. MTD/15-16/004199 dated 19/09/2015, invoice no. MTD/15-16/004520 dated 28/09/2015, invoice no. MTD/15-16/004521 dated 28/09/2015, invoice no. MTD/15-16/005033 dated 13/10/2015, invoice no. MTD/15-16/008198 dated 27/02/2016, of Rs. 1,54,176/- (One Lakh Fifty Four Thousand One Hundred Seventy Six Only) including VAT and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Ex-parte decree passed in Meditech's favor on 19/02/2022 and now execution to execute decree is to be filed on defendant address.

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address



**Next date of hearing:** Disposed

**(xix) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus GOODWILL HOSPITAL & RESEARCH CENTRE LTD**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ/306/2016

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/13-14/0163 dated 11/04/2013, invoice no. MTD/13-14/0467 dated 03/05/2013, invoice no. MTD/13-14/0493 dated 06/05/2013, invoice no. MTD/13-14/0683 dated 18/05/2013, invoice no. MTD/13-14/0763 dated 23/05/2013, invoice no. MTD/13-14/0813 dated 27/05/2013, invoice no. MTD/13-14/0900 dated 01/06/2013, invoice no. MTD/13-14/0901 dated 01/06/2013, invoice no. MTD/13-14/0999 dated 10/06/2013, invoice no. MTD/13-14/1225 dated 25/06/2013, invoice no. MTD/13-14/1498 dated 11/07/2013 of Rs. 2,48,399/- (Two Lakh Forty Eight Thousand Three Hundred Ninety Nine Only) including VAT and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Opposite party went in liquidation and case was withdrawn from court and claim was filed by Meditech before liquidator.

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** Disposed

**(xx) DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus SASA DIAGNOSTICS (I) PVT LTD**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ/575/2020

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTDG/17-18/2077 dated 06/09/2017, invoice no. MTDG/17-18/2284 dated 12/09/2017, invoice no. MTDG/17-18/2517 dated 16/09/2017, invoice no. MTDG/17-18/2556 dated 18/09/2017, invoice no. MTDG/17-18/3325 dated 06/10/2017, invoice no. MTDG/17-18/3362 dated 07/10/2017, invoice no. MTDG/17-18/3540 dated 11/10/2017, invoice no. MTDG/17-18/3832 dated 21/10/2017, invoice no. MTDG/17-18/3954 dated 24/10/2017, invoice no. MTDG/17-18/4099 dated 27/10/2017, invoice no. MTDG/17-18/4427 dated 03/11/2017, invoice no. MTDG/17-18/4435 dated 03/11/2017, invoice no. MTDG/17-18/4563 dated 07/11/2017, invoice no. MTDG/17-18/4586 dated 07/11/2017, invoice no. MTDG/17-18/4934 dated 17/11/2017, invoice no. MTDG/17-18/5005 dated 18/11/2017, invoice no. MTDG/17-18/5141 dated 22/11/2017, invoice no. MTDG/17-18/5275 dated 27/11/2017, invoice no. MTDG/17-18/5284 dated 27/11/2017, invoice no. MTDG/17-18/5722 dated 11/12/2017, invoice no. MTDG/17-18/5918 dated 18/12/2017,

invoice no. MTDG/17-18/6143 dated 25/12/2017, invoice no. MTDG/17-18/6811 dated 15/01/2018 of Rs. 2,67,946/- (Two Lakh Sixty Seven Thousand Nine Hundred Fourty Six Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Meditech filed recovery suit and decree passed in Meditech's favour on 28/11/2022.

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** Disposed

(xxi) **DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus VNU HEALTHCARE LLP**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ/922/2018

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/16-17/01086 dated 14/05/2016, invoice no. MTD/16-17/01119 dated 16/05/2016, invoice no. MTD/16-17/01127 dated 16/05/2016, invoice no. MTD/16-17/01140 dated 16/05/2016, invoice no. MTD/16-17/01284 dated 21/05/2016, invoice no. MTD/16-17/01287 dated 21/05/2016, of Rs. 1,50,010/- (One Lakh Fifty Thousand Ten Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Meditech filed recovery suit and ex parte decree passed in Meditech's favour 12/04/2024

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** Disposed

(xxii) **DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD Versus CITY DIAGNOSTIC CENTRE -ROHTAK**

**Court Name:** Dwarka Court

**Case Number:** CS SCJ/565/2020

**Facts of the Case:** The defendant purchased number of medical and lab instruments/reagents/kits from the Company, upon which the defendant was issued invoice no. MTD/18-19/06671 dated 24/09/2018, invoice no. MTD/18-19/06805 dated 25/09/2018, of Rs. 24,640/- (Twenty Four Thousand Six Hundred Fourty Only) including IGST and the defendant assured that the payments would be made within 60 days as agreed but the defendant has not cleared their entire liability towards the Company till date.

**Brief of the Case:** Decree of Rs. 24,640 was passed in our company favour on 17/04/2023 and now execution is to be filed on defendant address.

**Case Status:** Execution with Transfer Certificate to be filed at judgement debtor address

**Next date of hearing:** N/A

(xxiii) **DR MEDITECH SURGICAL AND DIAGNOSTICS INDIA PVT LTD VERSUS THE DY./ASSISTANT COMMISSIONER, CGST JANAKPURI DIVISION**

**Court Name:** Joint Commissioner CGST Appeals-II, Delhi

**Case Number:** Appeal No. 156JC/Central Tax/Appeal-II/Delhi/2024-25

**Facts of the Case:** Appellant was served upon a show cause notice dated 20.01.2023 to show cause to the Assistant Commissioner, CGST Janakpuri Division, CGST Delhi West as to why:

(i) Tax liability (short paid) amounting to Rs. 2523303/-, excess ITC availed as per GSTR-9 amounting to Rs. 232390/- and liability on reversal of ITC amounting to Rs. 622111/- are aggregate amounting to Rs. 3377804/- should not be demanded and recovered from them under section 73(1) of CGST Act, 2017.

(ii) Interest at the applicable rate should not be demanded and recovered from them on the aforesaid amount under section 73 of CGST Act, 2017 read with (iii) section 50(3) of CGST Act, 2017. recovered under section 73 of CGST Act, Penalty should not be demanded and 2017 read with section 122(2)(a) of CGST Act, 2017.

The above show cause notice was adjudicated by the Dy./Assistant Commissioner, CGST Janakpuri Division, CGST Delhi West (hereinafter referred to as 'the adjudicating authority' and/or 'the respondent') vide Order-In-Original No. 05/GST/Adj./H.S./AC/CGST/ 2022-23 dated 31.03.2023 (hereinafter referred to as 'the impugned order') wherein all the allegations of said show cause notice were upheld and penalty was imposed.

Aggrieved with the above said impugned order, the appellant preferred an appeal under section 107(1) of CGST Act, 2017. However, the said appeal was rejected vide Order- In-Appeal No. 174/ADC/Central Tax/Appeal-II/Delhi/2023-24 dated 19.10.2023 on the sole ground of time-barred without going into merits of the case. In the meantime, the Government issued a Notification No. 53/2023-Central Tax dated 02.11.2023 making provision to file delayed appeals before 31.01.2024 on payment of extra 2.5% besides initial 10% of tax amount as pre-deposit. Accordingly, the appellant had preferred an appeal.

**Brief of the Case:** Demand of alleged short paid tax and inadmissible ITC along with interest and penalty

**Case Status:** Rejected

**Next date of hearing:** N.A (Case rejected)

## GOVERNMENT AND OTHER STATUTORY APPROVALS

### **The below confirmation has been added:**

Our company has no pending licenses or registrations required to support its existing operations under any state or central law, regulation, or rule. All necessary licenses and registrations have been duly obtained and are currently in effect.

### **The details for Shop and Establishment has been updated in a table mentioned on page 300.**

Sr. No	Description	Registration/ License No.	Issuing Authority	Date of Certificate	Date of Expiry
1.	Registration Under the Delhi Shop and Commercial Establishment Act, 1958	2024197378	Labour Department-Delhi	October 20, 2024	Valid till Cancelled

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

## **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Mr. Dharam Deo Choudhary**  
**Managing Director**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

### **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Mr. Ram Nagina Choudhary**  
**Whole Time Director**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

### **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Ms. Deepa Choudhary**  
**Executive Director**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

### **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Mr. Janardan Pal**

**Non-Executive Director**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*



## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

### **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Mr. Pankaj Sharma**  
**Independent Director**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

### **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Mr. Om Prakash Pal**  
**Independent Director**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

### **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**

**Ms. Saurabh Verma**  
**Chief Financial Officer**

**Place: Delhi**

**Date: September 15, 2025**

*This space has been intentionally left blank*

## **DECLARATION**

I, hereby declare that, all the relevant provisions of Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Addendum to Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. I further certify that all the statements made in the Addendum to Draft Red Herring Prospectus are true and correct.

## **SIGNED BY THE DIRECTORS OF OUR COMPANY**

**Sd/-**  
**Mr. Manoj Kumar**  
**Company Secretary**

**Place: Delhi**  
**Date: September 15, 2025**

*This space has been intentionally left blank*